LetroSYM 2.5 Tablet

Description of LetroSYM 2.5 (Letrozole 2.5mg) tablet

The active ingredient of LetroSYM 2.5 tablets is Letrozole 2.5mg, a non-steroidal aromatase inhibitor which is mainly used in the treatment of hormone-receptor positive breast carcinoma in post-menopausal patients. The therapeutic effect of letrozole is because of its ability to inhibit oestrogen synthesis.

Indications of LetroSYM 2.5 (Letrozole 2.5mg) tablet

LetroSYM 2.5 is used as an adjuvant therapy of early breast cancer in post menopausal females, who are hormone receptor positive, and also in the management of advanced breast cancer or metastatic cancer.

Mechanism of action of LetroSYM 2.5 (Letrozole 2.5mg) tablet

Letrozole is a selective inhibitor of aromatase enzyme (cytochrome P450 19A1) and inhibits the peripheral conversion of androgens to oestrogen. This enzyme suppression forms the main substance of oestrogen production in the post-menopausal women.

How to consume of LetroSYM 2.5 (Letrozole 2.5mg) tablet

The optimal dosage schedule should be a single tablet per day at a fixed time. The tablet can be consumed either with or without food. The entire tablet should be taken whole with water and not crushed and chewed as this can change kinetics of absorption. The therapy can take many years depending on the stage of the disease and response to clinical therapy.

Side Effects of LetroSYM 2.5 (Letrozole 2.5mg) tablet  

1. Common side effects

• Hot flashes
• Fatigue or weakness
• Headache
• Pain in the bones

2. Serious side effects

• Loss of bone mineral loss resulting in osteoporosis
• Increased rate of fractures
• Allergic issues (rashes itchy, or swelling)

3. Rare side effects

• Severe allergic reactions
• Heart attacks or other complications like angine
• Drastic changes of mood and effect

Safety Advice for LetroSYM 2.5 (Letrozole 2.5mg) tablet

Patients taking Letrozole ought to have routine medical cheque-ups, such as bone mineral density assessment and lipid profile cheques. Since the medication decreases oestrogen, prolonged medication treatment can lead to bone loss and increase the risk of fractures.

Breastfeeding: Letrozole is not to be used during lactation because it may have an adverse effect on the baby.

Pregnancy: Letrozole is not to be used in pregnancy because of the possible harm of the fetus.

Alcohol: Intake of alcohol should be restricted since it can increase the side effect on the liver.

Liver: It is recommended that care be used in patients with hepatic impairment; periodical observation of liver functions is necessary.

Lungs: Pulmonary toxicity is not a common condition, but the patients are advised to report the new onset or worsening of cough, dyspnea, and chest pain to their doctor.

Kidney: Care should be taken in case of severe kidney failure.

Driving: Dizziness or fatigue may result with the use of the drug; patients should avoid driving or using heavy machinery in case of these effects.

Interaction of LetroSYM 2.5 (Letrozole 2.5mg) tablet  

• Drug-Drug Interaction :

Rifampicin × Letrozole

Rifampicin is a strong potent inducer of hepatic enzymes and it can lower plasma levels of letrozole thereby weakening its anticancer effects. It is recommended to monitor clinically.

Phenytoin × Letrozole

The increase of hepatic metabolism induced by Phenytoin and the potential reduction of the levels of Letrozole; therapeutic control and care are appropriate.

Carbamazepine × Letrozole

Carbamazepine is likely to enhance the hepatic enzyme activity thus lowering the concentration and efficacy of Letrozole.

Warfarin × Letrozole

Though a considerable interaction is not usual; it is recommended that monitoring be applied when the two drugs are used simultaneously because of anticoagulant response changes.

Ketoconazole × Letrozole

The CYP enzyme inhibitor ketoconazole may increase plasma levels of letrozole; the adverse events must be given particular attention.

• Drug-Food Interaction:

It has not been reported that Letrozole and food had any significant interaction in pharmacokinetics. Tablet can be given with or without concomitant food as per the choice of the patient or as per clinically convenient.

• Drug-Disease Interaction:

Osteoporosis:

The low bone mineral density and increase in fracture risk can be caused by the inhibition of oestrogen by Letrozole. Patients with pre-existing osteoporosis or low bone mass may need to have their bone density monitored and provide calcium and vitamin D as supplements.

Cardiovascular Disease:

Letrozole may elevate cholesterol levels, which may cause cardiovascular risk. Close monitoring is supposed to be used when patients had a history of cardiac disease or hyperlipidemia.

Hepatic Impairment:

The Letrozole metabolism in the liver dysfunctioned patients can be altered. During therapy, liver functioning tests are to be observed.

Renal Impairment:

Even though dose adjustment is not generally necessary, one should exercise caution when dealing with severe cases of renal dysfunction.

Contraindication of LetroSYM 2.5 (Letrozole 2.5mg) tablet  

The contraindications of letrozole are manifested not only in people with signs of hypersensitivity to the active substance or any of the excipients but also in pregnancy and lactation, which have teratogenic and infantile adverse effects. Its pharmacologic effect is post-menopausal, and therefore, it should not be used in pre-menopausal patients unless used together with ovarian suppression therapy.

Dosage of LetroSYM 2.5 (Letrozole 2.5mg) tablet  

The typical therapeutic protocol includes 1mg/day of medication taken at a point in time that is regular daily. The total period of treatment is also personalised and determines the treating oncologist and may take several years depending on clinical goals and treatment effectiveness.

Storage of LetroSYM 2.5 (Letrozole 2.5mg) tablet  

Store the formulation at room temperature, and prevent it against moisture and overheating. Keep the drugs locked away, preferably away from kids.

Missed Dose of LetroSYM 2.5 (Letrozole 2.5mg) tablet

In case of a missed dose, one should take it as soon as possible, with at least a long period between the dose and the next dose.

Other General Information of LetroSYM 2.5 (Letrozole 2.5mg) tablet

Continued use could cause long-term effects of dermatologic dryness and permanent joint stiffness; it is recommended that they be hydrated and exercise lightly to relieve pain. Patients are to be advised to keep their bones healthy by consuming a large amount of calcium and vitamin D in their diet and participating in regular weight-bearing exercises when it is medically possible. The oncologist ought to be able to cheque on the effectiveness of therapy and detect the bad incidents as early as possible. Patients should notify their physician as soon as they start to exhibit some unusual symptoms like constant aches in their bones, chest pain, or unnecessary fatigue.

FAQs of LetroSYM 2.5 (Letrozole 2.5mg) tablet

1. Why is it that Letrozole is only used in postmenopausal women?

Letrozole works by blocking aromatase which is an enzyme that produces oestrogen after menopause. In premenopausal women, ovarian activity is still capable of generating the large amount of oestrogen; hence the effects of a drug are constrained unless the ovarian suppression is performed simultaneously.

2. Is Letrozole associated with bone weakness?

Yes. Oestrogen is necessary in preserving bone density and its depletion may gradually weaken bone. Bone density cheques are commonly prescribed by the clinicians as long-term treatment.

3. Is Letrozole a weight gaining drug?

Direct adverse effects are not common, but weight gain may be caused by hormonal changes, a lack of exercise owing to fatigue in some patients.

4. What is the average length of time Letrozole should be used?

The drug is used normally in a period of five years and above depending on the staging of the tumour, the risk of its recurrence and the judgement of the physician who is treating the patient.

5. Is it possible that Letrozole influences cholesterol level?

Indeed. Others might develop hypercholesterolemia, and this will be a reason to repeat lipid profile monitoring.

6. Do you experience joint pain in the course of treatment?

Such symptoms as arthralgia and stiffness in the joints are common as a result of oestrogen deprivation. These complaints can be treated by gentle physical activities and supportive therapies.

Fact Box of LetroSYM 2.5 (Letrozole 2.5mg) tablet

Field	Details
Generic/Molecule Name	Letrozole
Therapeutic Class	Anti-neoplastic agent
Pharmacological Class	Aromatase Inhibitor
Dosage form	Injection
Habit forming	No
Indication	Hormone Receptor-positive Breast cancer

 

References

• FDA Prescribing Information – Femara (Letrozole) https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020275s053lbl.pdf
• European Medicines Agency (EMA) – Femara Summary of Product Characteristics https://www.ema.europa.eu/en/documents/product-information/femara-epar-product-information_en.pdf
• DrugBank – Letrozole Profile https://go.drugbank.com/drugs/DB01217
• National Cancer Institute (NCI) – Letrozole Drug Information https://www.cancer.gov/about-cancer/treatment/drugs/letrozole